Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 202Recurrence 53Neoplasms, Plasma Cell 19Neoplasms 12Immunoglobulin Light-chain Amyloidosis 10Hematologic Diseases 4Amyloidosis 4Renal Insufficiency 3Lymphoma, Non-Hodgkin 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Disease Progression 2Chromosome 17 deletion 2Waldenstrom Macroglobulinemia 1Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Hypoxia 1Hodgkin Disease 1Hematologic Neoplasms 1Disease 1Corneal Diseases 1Alzheimer Disease 1

Interventions

fludarabine phosphate 90Cyclophosphamide 85Mycophenolic Acid 67Peripheral Blood Stem Cell Transplantation 65Whole-Body Irradiation 59Tacrolimus 58Cyclosporine 46Busulfan 45Antilymphocyte Serum 39fludarabine 35Filgrastim 35Melphalan 33Methotrexate 28Radiotherapy 26Granulocyte Colony-Stimulating Factor 20Sirolimus 17Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 17Rituximab 14Stem Cell Transplantation 13Alemtuzumab 13thymoglobulin 11sargramostim 11Cyclosporins 11Therapeutics 10Flow Cytometry 10Cytarabine 10plerixafor 8Thiotepa 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × pomalidomide × Plasma cell × Clear all
NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Completed
320 enrolled 35 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡